Sanofi receives FDA approval of Priftin® (rifapentine) tablets for the treatment of latent tuberculosis infection

Following a priority review, the U.S. Food and Drug Administration has approved Priftin® (rifapentine) in combination with isoniazid (INH) for a new indication for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older at high risk of progression to tuberculosis (TB) disease. Approved in the United States since 1998, Priftin is an antimycobacterial used in combination with one or more antituberculosis drugs for the treatment of active pulmonary TB caused by Mycobacterium tuberculosis.

Read the press release here.

Source: Sanofi

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Sanofi

Published: Dec. 3, 2014, 8:04 p.m.

Last updated: Dec. 4, 2014, 4:05 a.m.

Print Share